Understanding PCSK9 and anti-PCSK9 therapies

被引：45

作者：

McKenney, James M. ^{[1
]}

机构：

[1] Virginia Commonwealth Univ, Natl Clin Res Inc, Sch Pharm, Richmond, VA 23294 USA

来源：

JOURNAL OF CLINICAL LIPIDOLOGY | 2015年 / 9卷 / 02期

关键词：

Proprotein convertase subtilisin kexin type 9 (PCSK9); LDL receptors; Statins; Dyslipidemia; Atherosclerotic cardiovascular disease; Monoclonal antibody; SUBTILISIN/KEXIN TYPE 9; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; DENSITY-LIPOPROTEIN CHOLESTEROL; MONOCLONAL-ANTIBODY; LDL RECEPTOR; AMG; 145; SERINE-PROTEASE; ATORVASTATIN; EFFICACY; STATIN;

D O I：

10.1016/j.jacl.2015.01.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Inhibitors of proprotein convertase subtilisin kexin type 9 (PCSK9) represent a new therapeutic category of drugs for the treatment of dyslipidemia and atherosclerotic cardiovascular disease. To appreciate the efficacy of these agents and interpret research results, it is important to understand the dynamic relationship between PCSK9, low-density lipoprotein-receptors, intrahepatic cholesterol synthesis, and blood cholesterol levels. Drugs which negate the action of PCSK9 can produce substantial reductions in atherogenic lipoprotein cholesterol-carrying particles and thereby hold the potential for further reducing events associated with atherosclerotic cardiovascular disease. This article will describe and discuss PCSK9 interactive mechanisms and apply them to the interpretation of clinical trial results, which involve PCSK9 monoclonal antibodies. (C) 2015 National Lipid Association. All rights reserved.

引用

页码：170 / 186

页数：17

共 66 条

[11] Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 [J].

Careskey, Holly E. ;

Davis, R. Aleks ;

Alborn, William E. ;

Troutt, Jason S. ;

Cao, Guoqing ;

Konrad, Robert J. .

JOURNAL OF LIPID RESEARCH, 2008, 49 (02) :394-398

[12] PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia [J].

Cariou, Bertrand ;

Ouguerram, Khadija ;

Zair, Yassine ;

Guerois, Raphael ;

Langhi, Cedric ;

Kourimate, Sanae ;

Benoit, Isabelle ;

Le May, Cedric ;

Gayet, Constance ;

Belabbas, Khaldia ;

Dufernez, Fabienne ;

Chetiveaux, Maud ;

Tarugi, Patrizia ;

Krempf, Michel ;

Benlian, Pascale ;

Costet, Philippe .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (12) :2191-U461

[13] Sequence variations in PCSK9, low LDL, and protection against coronary heart disease [J].

Cohen, JC ;

Boerwinkle, E ;

Mosley, TH ;

Hobbs, HH .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1264-1272

[14] Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia [J].

Cunningham, David ;

Danley, Dennis E. ;

Geoghegan, Kieran F. ;

Griffor, Matthew C. ;

Hawkins, Julie L. ;

Subashi, Timothy A. ;

Varghese, Alison H. ;

Ammirati, Mark J. ;

Culp, Jeffrey S. ;

Hoth, Lise R. ;

Mansour, Mahmoud N. ;

McGrath, Katherine M. ;

Seddon, Andrew P. ;

Shenolikar, Shirish ;

Stutzman-Engwall, Kim J. ;

Warren, Laurie C. ;

Xia, Donghui ;

Qiu, Xiayang .

NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2007, 14 (05) :413-419

[15] Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters [J].

Dong, Bin ;

Wu, Minhao ;

Li, Hai ;

Kraemer, Fredric B. ;

Adeli, Khosrow ;

Seidah, Nabil G. ;

Park, Sahng Wook ;

Liu, Jingwen .

JOURNAL OF LIPID RESEARCH, 2010, 51 (06) :1486-1495

[16] A new method for measurement of total plasma PCSK9: clinical applications [J].

Dubuc, Genevieve ;

Tremblay, Michel ;

Pare, Guillaume ;

Jacques, Helene ;

Hamelin, Josee ;

Benjannet, Suzanne ;

Boulet, Lucie ;

Genest, Jacques ;

Bernier, Lise ;

Seidah, Nabil G. ;

Davignon, Jean .

JOURNAL OF LIPID RESEARCH, 2010, 51 (01) :140-149

[17] Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial [J].

Fitzgerald, Kevin ;

Frank-Kamenetsky, Maria ;

Shulga-Morskaya, Svetlana ;

Liebow, Abigail ;

Bettencourt, Brian R. ;

Sutherland, Jessica E. ;

Hutabarat, Renta M. ;

Clausen, Valerie A. ;

Karsten, Verena ;

Cehelsky, Jeffrey ;

Nochur, Saraswathy V. ;

Kotelianski, Victor ;

Horton, Jay ;

Mant, Timothy ;

Chiesa, Joseph ;

Ritter, James ;

Munisamy, Malathy ;

Vaishnaw, Akshay K. ;

Gollob, Jared A. ;

Simon, Amy .

LANCET, 2014, 383 (9911) :60-68

[18] Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study [J].

Giugliano, Robert P. ;

Desai, Nihar R. ;

Kohli, Payal ;

Rogers, William J. ;

Somaratne, Ransi ;

Huang, Fannie ;

Liu, Thomas ;

Mohanavelu, Satishkumar ;

Hoffman, Elaine B. ;

McDonald, Shannon T. ;

Abrahamsen, Timothy E. ;

Wasserman, Scott M. ;

Scott, Robert ;

Sabatine, Marc S. .

LANCET, 2012, 380 (9858) :2007-2017

[19] Plasma PCSK9 preferentially reduces liver LDL receptors in mice [J].

Grefhorst, Aldo ;

McNutt, Markey C. ;

Lagace, Thomas A. ;

Horton, Jay D. .

JOURNAL OF LIPID RESEARCH, 2008, 49 (06) :1303-1311

[20]

Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602

← 1 2 3 4 5 6 7 →